by TractManager | May 30, 2019 | Health Technology Assessment
Health Problem: Obesity is a common condition in the United States, where approximately 37.7% of adults aged 20 years and older are considered obese. Data from 2013 to 2014 show a rate of obesity of 17.2% among younger individuals aged 2 to 19 years. Morbid...
by TractManager | May 28, 2019 | Emerging Technology Report
Tegsedi (inotersen) is an antisense oligonucleotide (ASO) that inhibits production of transthyretin that is intended for the treatment of polyneuropathy due to hereditary transthyretin (TTR) amyloidosis. Inotersen is administered weekly via subcutaneous injection.If...
by TractManager | May 28, 2019 | Emerging Technology Report
Tegsedi (inotersen) is an antisense oligonucleotide (ASO) that inhibits production of transthyretin that is intended for the treatment of polyneuropathy due to hereditary transthyretin (TTR) amyloidosis. Inotersen is administered weekly via subcutaneous injection.If...
by TractManager | May 22, 2019 | Emerging Technology Report
OTX-TP is an eye insert that delivers travoprost to the ocular surface for up to 90 days. It is proposed as an alternative to daily eye drops for lowering intraocular pressure in patients with glaucoma or ocular hypertension.If you have a Hayes login, click here to...
by TractManager | May 22, 2019 | Emerging Technology Report
OTX-TP is an eye insert that delivers travoprost to the ocular surface for up to 90 days. It is proposed as an alternative to daily eye drops for lowering intraocular pressure in patients with glaucoma or ocular hypertension.If you have a Hayes login, click here to...
Recent Comments